Savara Inc financial data

Symbol
SVRA on Nasdaq
Industry
Pharmaceutical Preparations
Location
6836 Bee Cave Road, Building 3, Suite 201, Austin, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
Mast Therapeutics, Inc. (to 4/25/2017), ADVENTRX PHARMACEUTICALS INC (to 3/1/2013), BIOKEYS PHARMACEUTICALS INC (to 5/15/2003)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.5K % -26.8%
Debt-to-equity 26.8 % -9.7%
Return On Equity 20.8K % +180%
Return On Assets -46.4 % -35.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 172M shares +26.8%
Common Stock, Shares, Outstanding 171M shares +26.2%
Entity Public Float 410M USD +158%
Common Stock, Value, Issued 172K USD +25.5%
Weighted Average Number of Shares Outstanding, Basic 212M shares +21.3%
Weighted Average Number of Shares Outstanding, Diluted 212M shares +21.3%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 22M USD +56.8%
Operating Income (Loss) -89.7M USD -68.4%
Net Income (Loss) Attributable to Parent -82.9M USD -69.6%
Earnings Per Share, Basic -0.43 USD/shares -38.7%
Earnings Per Share, Diluted -0.43 USD/shares -38.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 21.4M USD -22.6%
Assets, Current 226M USD +33.1%
Property, Plant and Equipment, Net 206K USD -25.6%
Operating Lease, Right-of-Use Asset 400K USD +300%
Other Assets, Noncurrent 1.11M USD -8.07%
Assets 239M USD +31.2%
Accounts Payable, Current 4.61M USD +43.2%
Employee-related Liabilities, Current 2.84M USD +30.3%
Accrued Liabilities, Current 8.18M USD +42.4%
Liabilities, Current 12.8M USD +42.7%
Operating Lease, Liability, Noncurrent 200K USD +300%
Other Liabilities, Noncurrent 128K USD -54.9%
Liabilities 39.5M USD +11.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 299K USD
Retained Earnings (Accumulated Deficit) -460M USD -22%
Stockholders' Equity Attributable to Parent 199M USD +36%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 299K USD
Liabilities and Equity 239M USD +31.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.6M USD -71.7%
Net Cash Provided by (Used in) Financing Activities 49K USD +88.5%
Net Cash Provided by (Used in) Investing Activities 10.8M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 171M shares +26.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.8M USD +45.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 536K USD +15.5%
Deferred Tax Assets, Valuation Allowance 73.9M USD +45.2%
Deferred Tax Assets, Gross 74.8M USD +46%
Operating Lease, Liability 344K USD +213%
Payments to Acquire Property, Plant, and Equipment 10K USD +150%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -81.7M USD -69.4%
Lessee, Operating Lease, Liability, to be Paid 390K USD +233%
Property, Plant and Equipment, Gross 2.28M USD +15.6%
Operating Lease, Liability, Current 200K USD +233%
Lessee, Operating Lease, Liability, to be Paid, Year Two 160K USD +196%
Lessee, Operating Lease, Liability, to be Paid, Year One 143K USD +127%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 46K USD +557%
Lessee, Operating Lease, Liability, to be Paid, Year Three 87K USD
Deferred Tax Assets, Operating Loss Carryforwards 44.7M USD +14.8%
Preferred Stock, Shares Authorized 1M shares 0%
Share-based Payment Arrangement, Expense 8.19M USD +142%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%